The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Official Title: A Phase 2, Randomized, Active-Controlled, Open-Label Study to Evaluate the Efficacy and Safety of LBL-007 in Combination With Tislelizumab Plus Chemotherapy as First-Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Study ID: NCT06010303
Brief Summary: This is a randomized, open-label study to compare how well LBL-007 works in combination with tislelizumab and chemotherapy versus tislelizumab and chemotherapy when given as the first-line treatment in participants with inoperable locally advanced or metastatic esophageal squamous cell carcinoma (ESCC).
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Anhui Provincial Hospital, Hefei, Anhui, China
The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
Peking Union Medical College Hospital, Beijing, Beijing, China
Fujian Medical University Union Hospital, Fuzhou, Fujian, China
Fujian Cancer Hospital, Fuzhou, Fujian, China
Lanzhou University Second Hospital, Lanzhou, Gansu, China
The Tumor Hospital Affiliated to Guangxi Medical University, Nanning, Guangxi, China
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
Anyang Cancer Hospital, Anyang, Henan, China
Nanyang Central Hospital, Nanyang, Henan, China
The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China
Henan Cancer Hospital, Zhengzhou, Henan, China
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Hunan Cancer Hospital, Changsha, Hunan, China
The First Peoples Hospital of Changzhou, Changzhou, Jiangsu, China
Nanjing Drum Tower Hospital,the Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China
Nantong Tumor Hospital Branch North, Nantong, Jiangsu, China
The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China
General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China
Shandong Cancer Hospital, Jinan, Shandong, China
The Second Affiliated Hospital of Shandong First Medical University, Taian, Shandong, China
Sichuan Cancer Hospital and Institute, Chengdu, Sichuan, China
Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital, Chengdu, Sichuan, China
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
National Cancer Center, Goyangsi, Gyeonggido, Korea, Republic of
Gachon University Gil Medical Center, Incheon, Incheon Gwang'yeogsi, Korea, Republic of
Chonnam National University Hwasun Hospital, Hwasungun, Jeonranamdo, Korea, Republic of
Seoul National University Hospital, Seoul, Seoul Teugbyeolsi, Korea, Republic of
Severance Hospital Yonsei University Health System, Seoul, Seoul Teugbyeolsi, Korea, Republic of
Asan Medical Center, Seoul, Seoul Teugbyeolsi, Korea, Republic of
The Catholic University of Korea, Seoul St Marys Hospital, Seoul, Seoul Teugbyeolsi, Korea, Republic of
Korea University Guro Hospital, Seoul, Seoul Teugbyeolsi, Korea, Republic of
Changhua Christian Hospital, Changhua, , Taiwan
Kaohsiung Medical University Chung Ho Memorial Hospital, Kaohsiung, , Taiwan
China Medical University Hospital, Taichung, , Taiwan
National Taiwan University Hospital, Taipei, , Taiwan
Taipei Veterans General Hospital, Taipei, , Taiwan
Ramathibodi Hospital Mahidol University, Bangkok, , Thailand
Siriraj Hospital, Bangkok, , Thailand
Songklanagarind Hospital (Prince of Songkhla University), Hat Yai, , Thailand
Hrh Princess Maha Chakri Sirindhorn Medical Center (Srinakharinwirot University), Ongkharak, , Thailand
Phramongkutklao Hospital, Ratchathewi, , Thailand
Name: Study Director
Affiliation: BeiGene
Role: STUDY_DIRECTOR